Analysts Offer Predictions for TG Therapeutics Q4 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at HC Wainwright boosted their Q4 2024 EPS estimates for shares of TG Therapeutics in a research note issued to investors on Monday, November 4th. HC Wainwright analyst E. White now forecasts that the biopharmaceutical company will earn $0.15 per share for the quarter, up from their prior estimate of $0.11. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.13 per share.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. TG Therapeutics’s revenue was down 49.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.73 earnings per share.

TGTX has been the subject of several other reports. B. Riley lifted their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. TD Cowen started coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. Finally, The Goldman Sachs Group upped their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $37.67.

TG Therapeutics Stock Up 5.1 %

TGTX stock opened at $27.17 on Wednesday. The firm has a market cap of $4.21 billion, a price-to-earnings ratio of -258.60 and a beta of 2.19. TG Therapeutics has a 1-year low of $9.81 and a 1-year high of $27.67. The firm has a fifty day moving average price of $23.57 and a two-hundred day moving average price of $20.26. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83.

Institutional Investors Weigh In On TG Therapeutics

A number of hedge funds have recently made changes to their positions in TGTX. NBC Securities Inc. raised its stake in shares of TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares in the last quarter. Quarry LP increased its stake in TG Therapeutics by 9.1% during the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 503 shares during the period. Private Advisor Group LLC raised its position in shares of TG Therapeutics by 3.9% during the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after buying an additional 542 shares in the last quarter. Blue Trust Inc. lifted its stake in shares of TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares during the period. Finally, KBC Group NV boosted its holdings in shares of TG Therapeutics by 30.5% in the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,092 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.